In a lean biotech environment with aggressive milestones, teams often accept reporting that is “good enough.” But those ...
In today’s Pharmaceutical Executive Daily, FDA approves Vybrique for erectile dysfunction, experts argue Phase III clinical ...
FDA has approved Vybrique, the first oral film formulation of sildenafil for the treatment of erectile dysfunction, offering ...
Veradermics Inc., a late clinical-stage biopharmaceutical company focused on hair restoration, raised $256.3 million in an ...
By giving small and mid-size biotechs access to real-world data and advanced analytics once reserved for large pharma, AI ...
After months of speculation, TrumpRx is live and offering Americans a variety of important medications at most-favored-nation prices. 1 Or, more accurately, it’s providing coupons for certain ...
In today’s Pharmaceutical Executive Daily, Susan G. Komen releases its 2026 breast cancer progress outlook, industry leaders ...
SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic ...
The FDA rejected AstraZeneca's subcutaneous Saphnelo application, delaying U.S. approval until 2026, despite positive ...
In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application ...
PE: What was your experience debuting Trialynx at JP Morgan Healthcare 2026? Schwab: It’s fantastic. This was the culmination ...
Eli Lilly is investing $3.5 billion in a new manufacturing facility in Lehigh Valley, Pennsylvania, to produce injectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results